Veradigm Inc. has made a $30 million strategic investment in Holmusk, a global behavioral health real-world evidence company. This collaboration aims to advance innovation in behavioral health and create the necessary evidence to drive the field forward. It involves adding cohorts of millions of behavioral health patients and related de-identified clinical data from Veradigm to Holmusk’s NeuroBlu Database, expanding its capacity for research on behavioral healthcare delivery and addressing complex behavioral health questions.
What You Should Know:
– Veradigm Inc. (NASDAQ: MDRX), a provider of healthcare data and technology solutions, announced it has made a $30M strategic investment in Holmusk, a global behavioral health real-world evidence company. The strategic investment builds on the strengths of each company to fuel innovation in behavioral health and create the evidence needed to move the field forward.
– In this new phase of the collaboration, cohorts of millions of behavioral health patients and related de-identified clinical data from Veradigm will be added to Holmusk’s NeuroBlu Database, a source for real-world data (RWD) that shows how behavioral healthcare is delivered. The NeuroBlu Database will now be able to power even more research and address challenging behavioral health questions that require the creation of targeted research cohorts.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: HitConsultant